<?xml version='1.0' encoding='utf-8'?>
<document id="30961507"><sentence text="Concomitant Use of Cotrimoxazole and Atazanavir in HIV-infected Patients: A Therapeutic Drug Monitoring and Pharmacovigilance Based Dual Approach."><entity charOffset="19-32" id="DDI-PubMed.30961507.s1.e0" text="Cotrimoxazole" /><entity charOffset="37-47" id="DDI-PubMed.30961507.s1.e1" text="Atazanavir" /><pair ddi="false" e1="DDI-PubMed.30961507.s1.e0" e2="DDI-PubMed.30961507.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30961507.s1.e0" e2="DDI-PubMed.30961507.s1.e1" /></sentence><sentence text="Cotrimoxazole is the main antibiotic used in primary prophylaxis for opportunistic infections in advanced HIV infection"><entity charOffset="0-13" id="DDI-PubMed.30961507.s2.e0" text="Cotrimoxazole" /></sentence><sentence text=" This drug can inhibit one of the metabolic pathways of atazanavir (ATV), such as the cytochromes P450 (CYP) 2C8/2C9 and could interfere with its safety and efficacy"><entity charOffset="56-66" id="DDI-PubMed.30961507.s3.e0" text="atazanavir" /></sentence><sentence text="" /><sentence text="We studied the drug-drug interaction (DDI) between cotrimoxazole and ATV by using therapeutic drug monitoring (TDM) and pharmacovigilance (PV) approaches"><entity charOffset="51-64" id="DDI-PubMed.30961507.s5.e0" text="cotrimoxazole" /></sentence><sentence text="" /><sentence text="We compared a group of patients treated with cotrimoxazole and receiving an ATV-based regimen to controls"><entity charOffset="45-58" id="DDI-PubMed.30961507.s7.e0" text="cotrimoxazole" /></sentence><sentence text=" This historical cohort analysis used data from Dat'AIDS in HIV-infected patients who had at least two lowest plasma concentrations (C-trough) of ATV during their outpatient follow-up" /><sentence text=" Likewise, we used the international pharmacovigilance data from VigiBase to evaluate the notifications of hyperbilirubinemia reported with ATV" /><sentence text="" /><sentence text="In the TDM analysis, the two groups of patients (treated with cotrimoxazole and controls) were almost homogeneous concerning the main baseline features"><entity charOffset="62-75" id="DDI-PubMed.30961507.s11.e0" text="cotrimoxazole" /></sentence><sentence text=" After at least six months of ATVbased regimen, there was no significant difference in the safety threshold of the ATV C-trough [with an adjusted odds ratio (aOR) of 1" /><sentence text="4 (95% CI: 0" /><sentence text="5 - 4" /><sentence text="4)] compared to controls" /><sentence text=" We observed similar results with the efficacy thresholds of ATV C-trough" /><sentence text=" Regarding the PV analysis, there was no difference in hyperbilirubinemia occurring with ATV when cotrimoxazole was concomitant, with an adjusted reporting odds ratio (aROR) of 0"><entity charOffset="98-111" id="DDI-PubMed.30961507.s17.e0" text="cotrimoxazole" /></sentence><sentence text="9 (95% CI: 0" /><sentence text="6 to 1" /><sentence text="2)" /><sentence text="" /><sentence text="This study showed a relevant concomitant use between Cotrimoxazole and ATV based on TDM and PV approaches"><entity charOffset="53-66" id="DDI-PubMed.30961507.s22.e0" text="Cotrimoxazole" /><entity charOffset="84-87" id="DDI-PubMed.30961507.s22.e1" text="TDM" /><entity charOffset="92-94" id="DDI-PubMed.30961507.s22.e2" text="PV" /><pair ddi="false" e1="DDI-PubMed.30961507.s22.e0" e2="DDI-PubMed.30961507.s22.e0" /><pair ddi="false" e1="DDI-PubMed.30961507.s22.e0" e2="DDI-PubMed.30961507.s22.e1" /><pair ddi="false" e1="DDI-PubMed.30961507.s22.e0" e2="DDI-PubMed.30961507.s22.e2" /><pair ddi="false" e1="DDI-PubMed.30961507.s22.e1" e2="DDI-PubMed.30961507.s22.e1" /><pair ddi="false" e1="DDI-PubMed.30961507.s22.e1" e2="DDI-PubMed.30961507.s22.e2" /></sentence><sentence text="" /></document>